Severe cardiomyopathy following treatment with the tumour necrosis factor-α inhibitor adalimumab for Crohn's disease
Author:
Affiliation:
1. Department of Cardiovascular Surgery; University Hospital Zurich; Raemi Street 100 8091 Zurich Switzerland
2. Department of Anaesthesia & Intensive Care Medicine; University Hospital Zurich; Zurich Switzerland
Publisher
Wiley
Subject
Cardiology and Cardiovascular Medicine
Reference11 articles.
1. TNFalpha blockade in human diseases: an overview of efficacy and safety;Lin;Clin Immunol,2008
2. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab;Scheinfeld;J Dermatol Treat,2004
3. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL);Mann;Circulation,2004
4. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial;Chung;Circulation,2003
5. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?;Listing;Arthritis Rheum,2008
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Heart failure associated with ustekinumab therapy for treatment of Crohn’s Disease;Drug and Therapeutics Bulletin;2023-06-30
2. Heart failure associated with ustekinumab therapy for treatment of Crohn’s Disease;BMJ Case Reports;2022-09
3. Acute Myopericarditis in the Setting of Crohn’s Colitis: Challenging Management Decisions;Cureus;2022-03-03
4. Dilated Cardiomyopathy in Pediatric Crohn’s Patient: Is It a Manifestation or Consequence of Therapy?;Cureus;2021-11-08
5. Psoriasis comorbidities and clinical implications when using biologics;Dermatological Reviews;2021-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3